Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

Study acronym: CONFIRM
StatusActive, Not Recruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 70 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Jun 10, 2026, no change to tracked fieldsv69-v70
  2. Study completion date: Dec 31, 2025 to Dec 31, 2026v68
  3. Site details revised at 1 of 106 sitesv67
  4. Study sites: 104 to 106
    • Study completion date: Mar 31, 2025 to Dec 31, 2025
    v66
  5. Re-verified, no change to tracked fieldsv65
Show 44 earlier versionsHide 44 earlier versions
  1. Study sites: 103 to 104v64
  2. Study completion date: Mar 29, 2024 to Mar 31, 2025
    • Site details revised at 70 of 103 sites
    v63
  3. Re-verified, no change to tracked fieldsv62
  4. Study completion date: Dec 29, 2023 to Mar 29, 2024v61
  5. 2 versions Re-verified since Mar 17, 2023, no change to tracked fieldsv59-v60
  6. Study completion date: Dec 30, 2022 to Dec 29, 2023v58
  7. Study sites: 104 to 103v57
  8. Re-verified, no change to tracked fieldsv56
  9. Site details revised at 2 of 104 sitesv55
  10. Study completion date: Dec 31, 2021 to Dec 30, 2022
    • Start date: Feb 8, 2005 to Feb 13, 2005
    • Site details revised at 1 of 104 sites
    v54
  11. 2 versions Re-verified since Jun 11, 2021, no change to tracked fieldsv52-v53
  12. Study sites: 85 to 104
    • Study completion date: Mar 31, 2021 to Dec 31, 2021
    v51
  13. Study completion date: Dec 31, 2020 to Mar 31, 2021v50
  14. 3 versions Re-verified since Mar 9, 2020, no change to tracked fieldsv47-v49
  15. Study completion date: Dec 31, 2019 to Dec 31, 2020
    • Site details revised at 1 of 85 sites
    v46
  16. Site details revised at 1 of 85 sitesv45
  17. Study sites: 84 to 85v44
  18. Study completion date: Jan 2, 2019 to Dec 31, 2019v43
  19. 2 versions Re-verified since Oct 23, 2018, no change to tracked fieldsv41-v42
  20. Site details revised at 1 of 84 sitesv40
  21. Re-verified, no change to tracked fieldsv39
  22. Study completion date: Jan 5, 2018 to Jan 2, 2019
    • Site details revised at 2 of 84 sites
    v38
  23. Re-verified, no change to tracked fieldsv37
  24. Enrollment target: 834 to 736v36 Show 4 more changesShow less
    • Study sites: 75 to 84
    • Primary completion date: Feb 2009 to Feb 27, 2009
    • Study completion date: Jan 2018 to Jan 5, 2018
    • Start date: Feb 2005 to Feb 8, 2005
  25. Re-verified, no change to tracked fieldsv35
  26. Study completion date: Jan 2017 to Jan 2018v34
  27. 4 versions Re-verified since Nov 2, 2015, no change to tracked fieldsv30-v33
  28. Study completion date: Jan 2016 to Jan 2017v29
  29. 3 versions Re-verified since Feb 18, 2015, no change to tracked fieldsv26-v28
  30. Study completion date: Jan 2015 to Jan 2016v25
  31. Study sites: 86 to 75
    • Study completion date: Sep 2013 to Jan 2015
    v24
  32. Study sites: 88 to 86v23
  33. Site details revised at 2 of 88 sitesv22
  34. Re-verified, no change to tracked fieldsv21
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
734 trials monitored
See 61 trials at risk
Breast Cancer
5,486 trials monitored
See 312 trials at risk
The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment.
Trial Details
NCT Number NCT00099437
Lead Sponsor AstraZeneca
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 736 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov